戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  ex vivo cytolytic activity and clearance of polyoma virus.
2 y conserved region of the large T antigen of polyoma virus.
3 nation inhibition antibodies to the human BK polyoma virus.
4 viruses such as Zika, hepatitis B, Adeno and Polyoma virus.
5 and usually fatal CNS infection caused by JC polyoma virus.
6 l responses in mice persistently infected by polyoma virus.
7 ding sites were found on middle T antigen of polyoma virus.
8 rstanding the replication cycle of oncogenic polyoma viruses.
9 %), cytomegalovirus 66 (3.75%), and BK virus polyoma virus 20 (1.13%) was low.
10                                              Polyoma virus, a highly oncogenic natural mouse DNA viru
11  acute and persistent phases of infection by polyoma virus, a mouse pathogen that is capable of poten
12                          In mice infected by polyoma virus, a natural mouse pathogen that establishes
13 g infection and preventing tumors induced by polyoma virus, a natural murine papovavirus.
14 l CD8(+) T cells in mice acutely infected by polyoma virus, a persistent mouse pathogen, specifically
15 lation for long-term control of infection by polyoma virus, a persistent mouse pathogen.
16 nation inhibition antibodies to the human JC polyoma virus and from 369 Amerinds from 13 tribes for h
17 he frequencies of precursor CTL specific for polyoma virus and MT(389-397) peptide were similar, indi
18                        Because the course of polyoma virus-associated nephropathy (PVAN) has not been
19 veloped fewer viral infections, particularly polyoma-virus-associated nephropathy (p = .021).
20 on procedure has been devised and applied to polyoma virus based on this rationale.
21  control infection with the B-cell-dependent polyoma virus, because plasma cells were markedly absent
22        Identification of risk factors for BK polyoma virus (BKPyV) without confounding by donor facto
23                           Reactivation of BK polyoma virus can result in destructive viral allograft
24              Importantly, CD94/NKG2A(+) anti-polyoma virus CD8 T cells appear to be essential for Ag-
25 racting (p53-TAg) or noninteracting (p53 and polyoma virus coat protein) pairs of proteins, treatment
26                This virus, termed cynomolgus polyoma virus (CPV), is antigenically and genomically re
27  two other alternative reading frames of the polyoma virus early region.
28 TL to recognize cells infected with a mutant polyoma virus encoding a MT truncated just proximal to t
29                                          The polyoma virus enhancer (PyE) is capable of conferring in
30 otein-2, CCAAT/enhancer-binding protein, and polyoma virus enhancer-3.
31  and origin-binding domains of papilloma and polyoma viruses evolved from a common ancestral protein
32 on, a mouse model was developed using murine polyoma virus expressing a defined CD4(+) T-cell epitope
33 including those from the herpes, retro-, and polyoma-virus families.
34 antigen (PyST), an early gene product of the polyoma virus, has been shown to cause cell death in a n
35                       Although papilloma and polyoma viruses have differences in capsid size (approxi
36                             Patients who had polyoma virus inclusions in renal allograft biopsies wer
37 as a therapeutic option in the management of polyoma virus induced graft failure.
38 d case of successful retransplantation after polyoma virus-induced renal allograft loss.
39 neonates having opposite susceptibilities to polyoma virus-induced tumors.
40 L/6 mice, a mouse strain highly resistant to polyoma virus-induced tumors.
41 IA-1: median, 7%; range, 2-15%) were seen in polyoma virus-infected allografts compared with 24% (ran
42 ) H-2k mice that specifically lyse syngeneic polyoma virus-infected cells and polyoma tumor cells.
43                                              Polyoma virus-infected MyD88 knockout mice generated str
44  characterize the lymphocytic infiltrates in polyoma virus-infected renal allografts.
45              The median time of diagnosis of polyoma virus infection after transplantation was 9.5 mo
46                       In summary, persistent polyoma virus infection both quantitatively and qualitat
47                                              Polyoma virus infection causes acute interstitial nephri
48                                 Asymptomatic polyoma virus infection documented by urine cytology or
49                  One animal had diarrhea and polyoma virus infection in the smooth muscle cells of th
50                                     Although polyoma virus infection is being increasingly recognized
51                                              Polyoma virus infection is characterized by lymphocytic
52             Previous graft loss secondary to polyoma virus infection is not a contraindication to ret
53  the B cells (CD20) in renal allografts with polyoma virus infection of 21% (range, 5-40%) compared w
54  The lymphocytic infiltrates of six cases of polyoma virus infection were compared with six cases of
55 pression predisposes cynomolgus monkeys to a polyoma virus infection with clinical consequences quite
56                                      Late in polyoma virus infection, early-strand mRNA levels are do
57 ersible graft failure is more prevalent with polyoma virus infection.
58  and enumerate MT389-397-specific CTL during polyoma virus infection.
59 ograft survival was seen in patients who had polyoma virus infection.
60 c T cells in allografts is characteristic of polyoma virus infection.
61                       There were 10 cases of polyoma virus infections in renal transplant recipients.
62 ific CD8(+) T cells following infection with polyoma virus, influenza virus, and Listeria monocytogen
63 54 to evaluate a rise in creatinine revealed polyoma virus interstitial nephritis.
64                                       The BK polyoma virus is a leading cause of chronic post kidney
65                                              Polyoma virus is a potent oncogenic pathogen when inocul
66                   The natural mouse pathogen polyoma virus is highly oncogenic in H-2k mice carrying
67 ain significant antibody titers to the human polyoma viruses JC and BK but do not appear to contain e
68 e in control of viral pathogens including JC polyoma virus (JCV) infection.
69 , with human herpes virus 3 (HHV3), JC human polyoma virus (JCV), HHV1, HHV4, HHV7, HHV5 showing the
70 HHV5), human papilloma virus (HPV), human JC polyoma virus (JCV), human endogenous retrovirus group K
71 hat some cases may be associated with the JC polyoma virus (JCV), which is also known to be latent in
72 bition antibody titers against the JC and BK polyoma viruses (JCV and BKV, respectively) are signific
73                Importantly, infection with a polyoma virus lacking MT389-397 and mutated in an MT236-
74 identified as a binding partner of the mouse polyoma virus large T antigen and later shown to possess
75                           Persistent anemia, polyoma virus-like nephritis (n = 2), and urinary calciu
76  The calcium bridge between the pentamers of polyoma viruses maintains capsid metastability.
77       Both torque teno virus and Merkel cell polyoma virus (MCPyV) were detected frequently in health
78 er, which is associated with the Merkel cell polyoma virus (MCPyV).
79                                  Merkel cell polyoma virus (MCV) has been implicated in a majority of
80                  Recently, a newly described polyoma virus, Merkel cell polyomavirus (MCPyV), was fou
81                       Chi3l1 ablation in the polyoma virus middle T (PyMT) breast cancer model genera
82 on into the mouse mammary tumor virus (MMTV)-polyoma virus middle T (PyV-mT) transgenic model.
83 mors in the mouse mammary tumor virus (MMTV)-polyoma virus middle T (PyVT) genetic model is delayed b
84  gene knockout and mouse mammary tumor virus-polyoma virus middle T antigen (MMTV-PyMT)-induced breas
85 growth factor receptors and proteins such as polyoma virus middle T antigen (MT).
86 titors in in vitro binding experiments using polyoma virus middle T antigen (MT).
87 itive cells (differentiated astrocytes) with polyoma virus middle T antigen (MTA).
88  (TK-/-) were crossed to mice expressing the polyoma virus middle T antigen (pMT) under the control o
89                       Viruses encoding mouse polyoma virus middle T antigen (PyMT) induced tumors, wh
90 V-A-based RCAS vectors encoding either mouse polyoma virus middle T antigen (PyMT) or c-Myc to elasta
91 ed with the mouse mammary tumor virus (MMTV)-Polyoma virus middle T antigen (PyMT) or MMTV-c-Neu tran
92 (MMTV) promoter-driven Ptn expressed in MMTV-polyoma virus middle T antigen (PyMT)-Ptn mouse breast c
93 erived from transgenic mice that express the polyoma virus middle T antigen (PyV-MT) in the mammary g
94 ssion using transgenic mice that express the polyoma virus middle T antigen (PyV-MT) in the mammary g
95                                              Polyoma virus middle T antigen (PyVmT) is a powerful vir
96 e G11 PLAP transgene was introduced into the polyoma virus middle T antigen mammary tumor model.
97 nse, we engineered mouse mammary tumor virus-polyoma virus middle T antigen mice with endothelial cel
98 ery of avian retroviruses encoding the mouse polyoma virus middle T antigen to elastase-tv-a transgen
99  after the somatic introduction of the mouse polyoma virus middle T antigen to mice with liver-specif
100 c PET and diffusion-weighted (DW)-MRI in the polyoma virus middle T antigen transgenic mouse model of
101 kt levels in total mouse mammary tumor virus-polyoma virus middle T antigen tumor lysates, suggesting
102                 Transgenic expression of the polyoma virus middle T antigen, under control of the mou
103 which activates the erythropoietin receptor; polyoma virus middle T antigen, which resembles an activ
104  in transgenic mice expressing the oncogene, polyoma virus middle T antigen.
105  limits mammary tumor initiation in the MMTV-polyoma virus middle T genetic model.
106  background of the mouse mammary tumor virus/polyoma virus middle T oncogene (MMTV-PyMT) mammary canc
107 metastases [mouse mammary tumor virus-driven polyoma virus middle T oncogene (MMTV-PyVT)].
108 were either crossed with mice expressing the polyoma virus middle T oncogene specifically in the mamm
109  mammary tumors due to the expression of the polyoma virus middle T oncogene.
110 nase signaling is the principle mechanism of polyoma virus middle T oncoprotein activation of c-fos e
111 oic acid inhibits transformation of cells by polyoma virus middle T oncoprotein.
112 of Src family kinases to membrane-associated polyoma virus middle T-antigen (PyMT) can result in the
113 l, we crossed MT1-MMP-deficient mice to MMTV-polyoma virus middle T-antigen (PyMT) mice.
114      We have isolated spontaneous mutants of polyoma virus middle T-antigen (PyMT) that do not activa
115 nd3, isolated from mice transformed with the Polyoma virus middle T-antigen is available commercially
116                                     Although polyoma virus middle T-driven tumors showed altered prim
117 of the late-appearing mammary tumors of MMTV-polyoma virus middle T;Nedd9(-/-) mice are characterized
118 hways that are influenced by IRS-1 using the polyoma virus middle-T (PyV-MT) transgenic mouse model o
119                                       Murine polyoma virus (MPyV) is a small DNA virus that induces t
120              In comparison to a case-matched polyoma virus-negative control group, the PVN patients w
121         The clinical course of patients with polyoma virus nephritis (PVN) is not well understood, pa
122  (n=7), T-cell-mediated rejection (n=4), and polyoma virus nephropathy (n=1).
123 ade in an attempt to reduce the incidence of polyoma virus nephropathy (PVAN).
124                                              Polyoma virus nephropathy after transplantation is belie
125 ivity and 57 days for patients who developed polyoma virus nephropathy.
126 me viremic and three patients (1%) developed polyoma virus nephropathy.
127  in a subset of renal allograft kidneys with polyoma virus nephropathy.
128     This effect did not occur with wild-type polyoma virus or RBCs expressing HEL alone.
129                     Capsids of papilloma and polyoma viruses (papovavirus family) are composed of 72
130          This highly focused CTL response to polyoma virus provides a valuable animal model to invest
131                                              Polyoma virus (PV) can cause interstitial nephritis and
132                                              Polyoma virus (Py) and simian virus 40 (SV40) travel fro
133                                              Polyoma virus (Py) differs from other small DNA tumor vi
134                                In this study polyoma virus (Py) is used as a tool to better define th
135                                  Using mouse polyoma virus (PyV) as a model of low-level persistent v
136  cells transferred to SCID mice responded to polyoma virus (PyV) infection with T cell-independent (T
137                              Using the mouse polyoma virus (PyV) persistent infection model, we recen
138 ighly susceptible to tumors induced by mouse polyoma virus (PyV), but CD8-deficient mice are resistan
139                                  Using mouse polyoma virus (PyV), we asked whether CD4(+) T cell help
140                                  Using mouse polyoma virus (PyV), we found that MHC class Ia-deficien
141                                          The polyoma virus region expressed early in the lytic cycle
142                         Leflunomide inhibits Polyoma virus replication in vitro and closely monitored
143        Transformation of cells in culture by polyoma virus requires integration of signals downstream
144 DNA extracted from affected kidneys detected polyoma virus sequences using primers for a highly conse
145 approach is used to explain the structure of polyoma virus, Simian Virus 40 and L-A virus capsids, wh
146    During the persistent phase of infection, polyoma virus-specific CD8 T cells that express CD94/NKG
147 ion is associated with Ag-specific recall of polyoma virus-specific CD8 T cells.
148 ) T-cell help for generating and maintaining polyoma virus-specific CD8(+) T cells.
149 CD4(+) T-cell help for the H-2(b)-restricted polyoma virus-specific CD8(+) T-cell response during acu
150 ly identified the immunodominant epitope for polyoma virus-specific CTL as the Dk-associated peptide
151 ly identified the immunodominant epitope for polyoma virus-specific CTL in tumor-resistant H-2k mice
152 d in an MT236-244 Dk anchor position induced polyoma virus-specific CTL recognizing neither MT389-397
153                                   The simian polyoma virus SV40 has been detected in specific human t
154 lations with no known exposure to the simian polyoma virus SV40, also were tested for antibodies to t
155 e a manifestation of the activity of a human polyoma virus termed "JC." Among a total of 1,835 person
156                          JC virus (JCV) is a polyoma virus that commonly infects humans.
157 g stimulated by the middle T-antigen (MT) of polyoma virus to address this question.
158                                              Polyoma virus tubulo-interstitial nephritis-associated g
159 xic effector function in mice susceptible to polyoma virus tumorigenesis.
160                                              Polyoma virus type BK (BKV) nephritis has emerged as an
161     In the present study, a hitherto unknown polyoma virus was detected in 12 of 57 cynomolgus monkey
162 e formation of long-term humoral immunity to polyoma virus was intrinsic to B cells and was independe
163 are highly susceptible to tumor induction by polyoma virus, whereas C57BR/cdj (BR) mice are highly re
164                      Infection with a mutant polyoma virus whose MT is truncated just before the MT38

 
Page Top